New drug cocktail shows promise for Hard-to-Treat myeloma

NCT ID NCT02718833

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a combination of four drugs—elotuzumab, pomalidomide, bortezomib, and dexamethasone—in 52 patients with multiple myeloma that has relapsed or stopped responding to at least two prior treatments. The goal is to see how many patients achieve a partial response or better, and to monitor side effects. The study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: elotuzumab, pomalidomide, bortezomib, and dexamethasone
What this could lead to: If successful, this combination could offer a new treatment option for patients with multiple myeloma that has returned or not responded to prior therapies.
What could go wrong: This is a small, early-phase trial (52 participants) with no control group, so results may not be definitive. The drug combination can cause serious side effects like infections and nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Mass General/North Shore Cancer Center

Danvers, Massachusetts, 01923, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Newton-Wellesley Hospital

Newton, Massachusetts, 02462, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Rochester

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.